{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021516","form_type":"8-K","ticker":"MD","cik":"0000893949","company_name":"Pediatrix Medical Group, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.904068+00:00","generated_at":"2026-06-22T11:01:58.638096+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pediatrix Q3 adjusted EPS $0.40 misses; FY2022 EBITDA guidance lowered to $240-245M","bullets":["Adjusted EPS from continuing operations $0.40 vs $0.46 YoY; GAAP EPS $0.35.","Net revenue $490M, down slightly from $493M YoY; same-unit revenue declined 3.2%.","Adjusted EBITDA $58.3M, down from $73.4M YoY; FY2022 guidance $240-245M.","CEO cites operational challenges in billing/collections and payor mix as headwinds.","Steps underway with R1 partner to improve revenue cycle; cost cuts starting Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021516","json":"https://secwatch.observer/filing/0000950170-22-021516.json","markdown":"https://secwatch.observer/filing/0000950170-22-021516.md","text":"https://secwatch.observer/filing/0000950170-22-021516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/893949/000095017022021516/0000950170-22-021516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/893949/000095017022021516/md-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T11:01:58.638096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ae749dfb1ba33a9721d002e4e45f8af5ed90321","claim":"Pediatrix Medical Group, Inc. reported the nine months ended September 30, 2022 results: revenue $1.46 billion.","evidence_excerpt":"For the nine months ended September 30, 2022, Pediatrix generated revenue from continuing operations of $1.46 billion, compared to $1.41 billion for the prior-year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/893949/000095017022021516/0000950170-22-021516-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Revenue","value":"$1.46 billion"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9f9a4ccfe45e714a6096f87ed42076764e9d59e1","claim":"Pediatrix Medical Group, Inc. reported the three months ended September 30, 2022 results: revenue $490 million, net income $29 million, EPS $0.35 per diluted share.","evidence_excerpt":"Pediatrix Medical Group, Inc. (NYSE: MD) , the nation’s leading provider of highly specialized health care for women, children and babies , today reported earnings from continuing operations of $0.35 per share for the three months ended September 30, 2022. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.40. For the 2022 third quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $490 million; • Income from continuing operations of $29 million; and • Adjusted EBITDA of $58 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/893949/000095017022021516/0000950170-22-021516-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$490 million"},{"label":"Net income","value":"$29 million"},{"label":"EPS","value":"$0.35 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}